Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880240 | 0.94 | ALDH1A1 (0.42) | ALDH1A1HSD17B10TDP1RAPGEF4GAA | |
| SCHEMBL2055455 | 0.85 | FFAR4 (0.39) | ALDH1A1HSD17B10TDP1RAPGEF4FFAR4 | |
| SCHEMBL2055457 | 0.84 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TDP1RAPGEF4GAA | |
| SCHEMBL30990667 | 0.84 | FFAR4 (0.38) | ALDH1A1HSD17B10TDP1RAPGEF4FFAR4 | |
| SCHEMBL22447746 | 0.84 | FFAR4 (0.38) | ALDH1A1HSD17B10TDP1RAPGEF4FFAR4 | |
| SCHEMBL841739 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TDP1RAPGEF4TSHRGAA | |
| SCHEMBL27310696 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TDP1RAPGEF4TSHRGAA | |
| SCHEMBL28188557 | 0.80 | RAPGEF4 (0.43) | ALDH1A1RAPGEF4TSHRKDM4EFFAR4 | |
| SCHEMBL10279153 | 0.80 | FABP3 (0.37) | ALDH1A1HSD17B10TDP1RAPGEF4GAA | |
| SCHEMBL30990630 | 0.79 | CA1 (0.33) | ALDH1A1HSD17B10TDP1RAPGEF4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897088-B | Phenylalanine derivative containing N- (2-oxoethyl) benzene sulfonamide and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| CN-108440389-B | 3,4, 5-trihydroxybenzoic acid derivative and preparation method and application thereof | 山东大学 | 2020-05-29 | — | — | CN | claimed |
| CN-110452146-A | Trifluoromethyl seleno-amino acids derivative and preparation method thereof | UNIV WUHAN TECH | 2019-11-15 | — | — | CN | claimed |
| CN-109897088-A | Phenylalanine derivative and the preparation method and application thereof containing N- (2- oxoethyl) benzsulfamide | 山东大学 | 2019-06-18 | — | — | CN | claimed |
| CN-108440389-A | 3,4,5-trihydroxy benzoic acid derivative and the preparation method and application thereof | 山东大学 | 2018-08-24 | — | — | CN | claimed |
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| WO-2013102936-A1 | N-(3-((DIETHYLAMINO) METHYL)-4-HYDROXYPHENYL)-N-(QUINOLIN-4-YL) SULFONAMIDES FOR THE TREATMENT OF TUBERCULOSIS AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-11 | — | — | WO | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | THE UNIVERSITY OF NOTTINGHAM (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025262003-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12428376-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | WYETH | 2006-02-02 | — | — | US | disclosed |
| US-6583280-B1 | Antitumor tetraamines; chiral compounds conformationally restricted polyamine analogues; diminish the ability to aggregate DNA seen in the parent polyamines; spermine, norspermine, cyclospermine analogues; 1,4-diazocines | SAAB-ISHMAIL NADA H (US) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | ALDH1A1 4260/4885HSD17B10 733/4885TDP1 3878/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | ALDH1A1 1700/4885HSD17B10 1252/4885TDP1 613/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | ALDH1A1 844/4885HSD17B10 187/4885TDP1 895/4885 |
| US-12428376-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885HSD17B10 1193/4885TDP1 2573/4885 |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | ITGA2, ITGB2, ITGB1 | ALDH1A1 814/4885HSD17B10 3114/4885TDP1 4504/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | ALDH1A1 478/4885HSD17B10 319/4885TDP1 3723/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | ALDH1A1 2041/4885HSD17B10 1607/4885TDP1 882/4885 |
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 139/4885HSD17B10 20/4885TDP1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.